Abstract:figure legend A head‐to‐head comparative analysis of two new mouse models of non‐ischaemic heart failure with reduced ejection fraction (HFrEF) and cardiometabolic heart failure with preserved ejection fraction (HFpEF) disclosed key differences regarding several pathophysiological features. The HFrEF left ventricle was characterized by systolic dysfunction, with accompanying fibrosis and pronounced cardiomyocyte hypertrophy, and HFrEF cardiomyocytes exhibited impaired calcium handling and damaged mitochondria. In contrast, the HFpEF left ventricle experienced a substantial increase in myocardial stiffness and a heightened inflammatory state, with a subtler hypertrophic response. In contrast to HFrEF, HFpEF cardiomyocytes displayed a rather enhanced but asynchronous calcium release, with comparably impaired mitochondria. Protein hyperacetylation was considerably more drastic in the HFpEF heart. Heart failure (HF) is a heterogeneous condition that can be categorized according to the left ventricular ejection fraction (EF) into HF with reduced (HFrEF) or preserved (HFpEF) EF. Although HFrEF and HFpEF share some common clinical manifestations, the mechanisms underlying each phenotype are often found to be distinct. Identifying shared and divergent pathophysiological features might expand our insights on HF pathophysiology and assist the search for therapies for each HF subtype. In this study, we evaluated and contrasted two new murine models of non‐ischaemic HFrEF and cardiometabolic HFpEF in terms of myocardial structure, left ventricular function, gene expression, cardiomyocyte calcium handling, mitochondrial polarization and protein acetylation in a head‐to‐head fashion. We found that in conditions of similar haemodynamic stress, the HFrEF myocardium underwent a more pronounced hypertrophic and fibrotic remodelling, whereas inflammation was greater in the HFpEF myocardium. We observed opposing features on calcium release, which was diminished in the HFrEF cardiomyocyte but enhanced in the HFpEF cardiomyocyte. Mitochondria were less polarized in both HFrEF and HFpEF cardiomyocytes, reflecting similarly impaired metabolic capacity. Hyperacetylation of cardiac proteins was observed in both models, but it was more accentuated in the HFpEF heart. Despite shared features, unique triggering mechanisms (neurohormonal overactivation in HFrEF vs. inflammation in HFpEF) appear to determine the distinct phenotypes of HF. The findings of the present research stress the need for further exploration of the differential mechanisms underlying each HF subtype, because they might require specific therapeutic interventions. Key points The mechanisms underlying heart failure with either reduced (HFrEF) or preserved (HFpEF) ejection fraction are often found to be different. Previous studies comparing pathophysiological traits between HFrEF and HFpEF have been conducted on animals of different ages and strains. The present research contrasted two age‐matched mouse models of non‐ischaemic HFrEF and cardiometabolic HFpEF to uncover divergent and shared features. We found that upon similar haemodynamic stress, the HFrEF heart experienced a more pronounced hypertrophic and fibrotic remodelling, whereas inflammation appeared to be greater in the HFpEF myocardium. Calcium release was diminished in the HFrEF cardiomyocyte and enhanced in the HFpEF cardiomyocyte. Mitochondria were comparably less polarized in both HFrEF and HFpEF myocytes. Hyperacetylation of proteins was common to both models, but stronger in the HFpEF heart. Casting light on common and distinguishing features might ease the quest for phenotype‐specific therapies for heart failure patients.

Abstract P380: Common And Distinct Signatures Of Interstitial And Perivascular Fibrosis In Mouse Models Of Hypertensive Heart Disease

Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy

Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction

Regulation of cardiac fibrosis in mice with TAC/DOCA‐induced HFpEF by resistin‐like molecule gamma and adenylate cyclase 1

Abstract 399: End-stage Heart Failure Causes Severe Lung Fibrosis and Dysfunction

Gradual hypertensive response in aortic alterations and myocardial inflammatory activation in progressing HFpEF in mice

Abstract 13694: Hsf1 Attenuates Pressure Overload Induced-cardiac Fibrosis via Inhibiting Smad3 Phosphorylation and Nuclear Translocation

Abstract P2083: Heart Failure With Preserved Ejection Fraction Mouse Model Development With Aav-renin

Distinguishing pathophysiological features of heart failure with reduced and preserved ejection fraction: A comparative analysis of two mouse models

Morphometric, Hemodynamic, And Multi-Omics Analyses In Heart Failure Rats With Preserved Ejection Fraction

Inflammation and fibrosis in murine models of heart failure

Gene expression and gene associations during the development of heart failure with preserved ejection fraction in the Dahl salt sensitive model of hypertension

The Association Between Myocardial Fibrosis and Depressed Capillary Density in Rat Model of Left Ventricular Hypertrophy

Gene expression analysis to identify mechanisms underlying heart failure susceptibility in mice and humans

Comparison of mouse models of heart failure with reduced ejection fraction

Abstract MP02: Angiotensin II Mediates Microvascular Rarefaction In Vivo and Exacerbates Endothelial-To-Mesenchymal Transition In Vitro

Cardiac structural remodeling in hypertensive cardiomyopathy

Abstract P2004: T Lymphocytes Promote Diastolic Dysfunction And Fibrosis In A Non-Hypertensive Angiotensin II Mouse Model Of Heart Failure

Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease

A New Ex Vivo Model to Study Cardiac Fibrosis in Whole Mouse Hearts

Abstract 13237: Single Cell Transcriptomes Reveal Novel Macrophage and Endothelial Subtypes in Pulmonary Hypertension